HC Wainwright & Co. Reiterates Buy on Reviva Pharmaceuticals, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Reviva Pharmaceuticals (NASDAQ:RVPH) and maintained a price target of $14.
June 20, 2024 | 10:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Reviva Pharmaceuticals and maintained a price target of $14, indicating confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a $14 price target by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. It suggests confidence in the company's future performance and could lead to increased investor interest and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100